Company Performance - TriSalus Life Sciences, Inc. reported a quarterly loss of $0.33 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, representing an earnings surprise of -65% [1] - The company posted revenues of $9.17 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.04%, but showing an increase from $6.46 million in the same quarter last year [2] - Over the last four quarters, the company has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - TriSalus Life Sciences, Inc. shares have declined approximately 2.2% since the beginning of the year, while the S&P 500 has gained 0.2% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $10.69 million, and for the current fiscal year, it is -$0.60 on revenues of $44.3 million [7] - The outlook for the Medical - Products industry, to which TriSalus belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact the stock's performance [8]

Trisalus Life Sciences (TLSI) Q1 2025 Earnings Call May 15, 2025 08:00 AM ET Speaker0 Good morning and welcome to the Trisales Life Sciences First Quarter twenty twenty five Earnings Conference Call. Currently, all participants are on a listen only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Alex Grossman, associate director with LifeSci Advisors. Please ...

Revenue and Sales Performance - TriSalus reported a revenue increase driven primarily by sales of its PEDD infusion systems, particularly the TriNav, with a gross margin that allows for substantial funding of growth and R&D [227][230]. - Revenue increased by $2.7 million, or 42.0%, for the three months ended March 31, 2025, compared to the same period in 2024, primarily due to increased sales of TriNav [239]. Product Development and Clinical Trials - The company launched the TriNav LV Infusion System and TriGuide Guiding Catheter in 2024, expanding its PEDD device portfolio to optimize therapeutic delivery for larger vessels [215][216]. - A registry study called PROTECT aims to enroll 100 patients and is expected to expand the addressable market by approximately 50,000 procedures, representing an incremental $400 million market opportunity [217]. - The company completed Phase I clinical trials for nelitolimod and is exploring partnerships for further development, with data expected in 2025 [218]. - The MDACC Agreement was modified and extended to include a sixth year, enhancing collaboration for ongoing clinical studies [222]. Financial Position and Cash Flow - Cash and cash equivalents were approximately $13.0 million at March 31, 2025, with a minimum cash requirement increased from $5.0 million to $10.0 million [250]. - Net cash used in operating activities was $4.5 million for the three months ended March 31, 2025, compared to $10.9 million for the same period in 2024 [251]. - Net cash provided by financing activities was $9.7 million for the three months ended March 31, 2025, primarily from the First Delayed draw under the OrbiMed Credit Agreement [256]. Expenses and Losses - Gross profit increased by $2.2 million, or 39.8%, for the three months ended March 31, 2025, with gross margin decreasing to 83.7% from 85.0% [241]. - Research and development expenses decreased by $2.5 million, or 43.6%, for the three months ended March 31, 2025, primarily due to reduced clinical trial expenses [242]. - General and administrative expenses increased by $0.3 million, or 7.4%, for the three months ended March 31, 2025, mainly due to professional services related to filing and audit expenses [245]. - Net loss available to common stockholders was $10.4 million for the three months ended March 31, 2025, compared to a net loss of $13.2 million for the same period in 2024 [238]. Funding and Capital Requirements - TriSalus secured a $10 million loan under the OrbiMed Credit Agreement, contingent on achieving a $30 million revenue base [221]. - The company anticipates gross proceeds of approximately $22 million from a private placement of 5.5 million shares at $4.00 per share, closing on May 2, 2025 [225]. - The company expects to finance its cash needs through a combination of securities offerings, debt financings, collaborations, strategic alliances, and licensing arrangements [260]. - There is substantial doubt regarding the company's ability to continue as a going concern as of March 31, 2025, due to its reliance on generating sufficient cash flows or obtaining additional capital [263]. - If the company is unable to raise additional capital, it may have to delay or terminate product development efforts [261]. - The company may face dilution of existing ownership interests if it raises additional capital through equity or convertible debt securities [260]. Regulatory and Compliance Matters - TriSalus received a permanent HCPCS code for the TriNav Infusion System effective January 1, 2024, which may enhance reimbursement clarity and support sales [214]. - The expiration of the TPT payment program in December 2023 poses a risk to maintaining current pricing and gross margins for TriNav [219]. - The company is subject to affirmative and restrictive covenants under the OrbiMed Credit Agreement, which may limit its operational flexibility [260]. - The company does not currently have any off-balance sheet financing arrangements or relationships with unconsolidated entities [266]. - The company’s critical accounting policies have not changed significantly during the three months ended March 31, 2025, compared to the previous year [267]. Other Financial Liabilities - The fair value of the SEPA, warrant, and revenue base redemption liabilities changed by $3.4 million, resulting in a loss of $0.8 million for the three months ended March 31, 2025 [247]. - The company has paid Dynavax $12.0 million as of March 31, 2025, with potential additional payments of up to $158 million upon achieving certain milestones related to nelitolimod [265]. - The company may be required to pay up to $80 million upon achieving certain commercial milestones for nelitolimod, subject to obtaining marketing approval [265].

NOW THEREFORE, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the Company and each Investor, severally and not jointly, agree as follows: 1. Definitions. As used in this Agreement, the following terms shall have the following respective meanings: Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this "Agreement") is dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the "Company") ...

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________ FORM 10-K __________________________________ (Mark One) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number 001-39813 _____________________________ ...

TriSalus Life Sciences, Inc. (TLSI) shares soared 6.6% in the last trading session to close at $5.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.5% gain over the past four weeks.The recent surge in TriSalus Life Sciences Inc.'s shares can be attributed to its strong fourth quarter and full-year 2024 results, marked by 44% YoY revenue growth in the fourth quarter and 59% for the full year, driven by the TriNav Infusion Sys ...

Trisalus Life Sciences (TLSI) Q4 2024 Earnings Call March 27, 2025 04:49 PM ET Company Participants Jeremy Feffer - Managing DirectorMary Szela - CEO, President & DirectorJames Young - CFOCarl Byrnes - Managing DirectorRichard Marshall - Medical DirectorWilliam Plovanic - Managing Director - Equity Research Conference Call Participants Justin Walsh - Director & Research AnalystFrank Takkinen - Senior Research AnalystNone - Analyst Operator Good morning, and welcome to the Trisales Life Sciences Fourth Quart ...

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity ...

TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.36 per share when it actually produced a loss of $0.40, delivering a surprise of -11.11%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.TriSalus Life Sciences, ...

Financial Results Announcement - TriSalus Life Sciences, Inc. announced preliminary unaudited financial results for the year and quarter ended December 31, 2024 [4] - The financial results were disclosed in a press release dated January 23, 2025, attached as Exhibit 99.1 to the Form 8-K [4] Form 8-K Filing Details - The information in Item 2.02 of the Form 8-K is furnished and not deemed "filed" under the Securities Exchange Act of 1934 [5] - The press release is incorporated by reference into the Form 8-K [4] Signatory Information - The report was signed by James Young, Chief Financial Officer of TriSalus Life Sciences, Inc., on January 23, 2025 [9]